 |
 |
 |
 |
|
| |
 |
| Reports on Overseas' Conferences and Meetings |
|
| |
|
| |
A Society Participation Report on the American Society of
Clinical Oncology 46th Annual Meeting and Exposition |
Kunihiro Tsukasaki
Department of Molecular Medicine and Hematology |
The American Society of Clinical Oncology (ASCO) 46th Annual Meeting and Exposition was held in MaCormick Convention Center, Chicago, IL, USA, during June 4-8, 2010. I, Lecturer Takuya Fukushima and Graduate Student Hidehiro Itonaga from Department of Molecular Medicine and Hematology attended the meeting.
In contrast to the less participants last year because of H1N1 influenza virus, there were more than 3,000 presentations and about 30,000 participants in the 2010 ASCO annual meeting. Dr. Blayney at Michigan University, president of this meeting, programmed the sessions focusing on research and management of cancer in the catch-phrase of “Advancing Quality through Innovation“.
In the Plenary Session, a P-3 double-blind study comparing anti-CTLA-4 Ab (ipilimumab) with GP100 peptide vaccine in patients with previously treated advanced melanoma indicated that the former was superior on tumor response and overall survival. Also in this session, promising clinical-activity of the ALK inhibitor PF-02341066 in patients with EML4-ALK positive, non-small cell lung cancer was presented.
There were 264 presentations on hematological malignancy, including dose- and timing-modification of molecular-targeting agents used in standard treatment, new generation of the agents and optimization of standard therapy by early evaluation of tumor response. Among them, follows were prominent: Effectiveness of maintenance therapy with anti-CD20 Ab rituximab and immunomodulating agent lenalidomide respectively for follicular lymphoma and multiple myeloma indicated by P-3 studies. Effectiveness of new-generation tyrosine klnases, dasatinib and nilotinib, for the treatment of bcr/abl-positive chronic myeloid leukemia as compared to imatinib indicated by P-3 studies. Effectiveness of early FDG/PET analysis for dose reduction of chemotherapy in advanced Hodgkin’s lymphoma suggested by an observational study.
Every year at ASCO meeting, I have been impressed with the results of P-3 studies changing the standard treatment and those of promising new agents and modalities. Next meeting will be held at Chicago again in 2011. |
|
Hidehiro Itonaga
Department of Molecular Medicine and Hematology
|
| I attended the American Society of Clinical Oncology 2010 (ASCO2010) on June 2010.
ASCO2010 was held in MaCormick Convention Center, which was the largest convention center in the USA. The number of participants amounted to more than 40,000 from all over the world. The topics in ASCO2010 were about not only hematologic malignancies, but also solid tumors.
Three themes about hematologic malignancies had attracted considerable attention in ASCO2010.
The phase 3 studies about tyrosine kinase inhibitor for newly diagnosed chronic myeloid leukemia (CML) patients showed the superiority of dasatinib and nilotinib compared to imatinib. The progress of the molecular-targeting therapy for CML was impressive.
The first-line therapy and maintenance therapy with bortezomib or lenalidomide showed advanced effectiveness on progression free survival. Those results also suggested the significance of high-dose chemotherapy with autologous stem cell transplantation was gradually decreasing.
There were many presentations about azacitidine and decitabine, which were DNA demethylating agents, and cloforabine which was a purine nucleoside analogue for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). New effective treatments, especially in elderly AML and MDS patients were under development.
The most advanced clinical research in ASCO2010 was informative. The great effort of many researchers impressed me.
|
|
|
|
|
|
| |
|
|
|
